BRAF and ameloblastoma: For the unicystic ameloblastomas, in the present study, it was observed positive immunoexpression of BRAF V600E for either luminal, intraluminal and mural subtypes, confirming that these three histological subtypes may be positive for BRAF V600E mutation, as previously defined (11).